James V. Caruso - Jun 23, 2023 Form 4 Insider Report for Cellectar Biosciences, Inc. (CLRB)

Role
President and CEO, Director
Signature
/s/ Christina Blakley, Attorney in-fact for James V. Caruso
Stock symbol
CLRB
Transactions as of
Jun 23, 2023
Transactions value $
$0
Form type
4
Date filed
12/12/2023, 08:04 PM
Previous filing
Jan 18, 2023
Next filing
Jun 18, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CLRB Common Stock Award $0 +40.6K +469.86% $0.00 49.2K Dec 8, 2023 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CLRB Stock option (right to buy) Award $0 +261K $0.00 261K Jun 23, 2023 Common Stock 261K $1.68 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option was contingently granted on January 16, 2023, subject to approval by Cellectar's stockholders of Cellectar's amended 2021 Stock Incentive Plan at Cellectar's 2023 Annual Meeting of Stockholders. Such stockholder approval was obtained on June 23, 2023. Because January 16, 2023 was a federal holiday, the option was priced on the following trading day.
F2 This option shall vest over a period of three years from January 17, 2023, with 1/3 vesting on the first anniversary of January 17, 2023 and the remainder vesting in 24 equal monthly installments over a 24-month period beginning on the first anniversary of January 17, 2023.